Sanara MedTech, Inc. SMTI 深 沪
等待开盘 03-26 09:30:00 美东时间
16.495
-1.585
-8.77%
华盛通- 最 高18.325
- 今 开18.14
- 成交量 27.07万股
- 最 低 16.16
- 昨 收 18.08
- 总市值 1.47亿
- 52周最高 35.95
- 市盈率 静 --
- 换手率 3.03%
- 52周最低 16.16
- 委 比 51.04%
- 总股本 893.57万
- 历史最高 53.85
- 量 比 4.31
- 振 幅 11.97%
- 历史最低 16.16
- 每 手 1
- 风险率 4.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
Sanara MedTech Affirms FY2026 Sales Guidance of $116.000M-$121.000M
Sanara MedTech (NASDAQ:SMTI) affirms FY2026 sales outlook from $116.000 million-$121.000 million to $116.000 million-$121.000 million.
03-24 19:06
Sanara MedTech Q4 EPS $(0.13) Misses $0.11 Estimate, Sales $27.546M Beat $27.400M Estimate
Sanara MedTech (NASDAQ:SMTI) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $0.11 by 218.18 percent. This is a 230 percent decrease over earnings of $0.10 per share from the
03-24 19:03
Sanara MedTech Announces Publication Of Peer-Reviewed Study Evaluating Economic And Clinical Value Of CellerateRX Surgical Powder In Journal Of Medical Economics
Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care
03-11 19:31
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
HC Wainwright & Co. Reiterates Buy on Sanara MedTech, Maintains $36 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Sanara MedTech (NASDAQ:SMTI) with a Buy and maintains $36 price target.
01-27 02:40
Sanara MedTech Expects Q4 Revenue To Be $27.2M-$27.7M, Up ~3%-5%, Compared To $26.3M In Q4 Of 2024
Sanara MedTech Inc. ("Sanara MedTech," "Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical
01-23 20:34
Sanara MedTech's BIASURGE Advanced Surgical Solution Product Receives Innovative Technology Contract From Vizient
Contract awarded for products that bring improvement to the healthcare industryFORT WORTH, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara MedTech," "Sanara," the "Company," "we," "our" or "us")
01-08 05:09
Sanara MedTech And Biomimetic Innovations Advance Strategic Alliance; Sanara Reaffirms Plans To Launch OsStic Bio‑Adhesive To US Commercial Market In Q1 2027
Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic's granted patent in 2025FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company,"
2025-12-10 21:44
Sanara MedTech to Participate in the Piper Sandler 37th Annual Healthcare Conference on December 3rd
Sanara MedTech Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference, where management will present on December 3, 2025. Presentation materials and a live webcast will be available on the Company’s investor relations website. Sanara develops surgical products to improve outcomes and reduce costs in the surgical market.
2025-11-19 12:30
